Bob Bradway, Amgen CEO (Scott Eisen/Bloomberg via Getty Images)
October 31, 2024 07:03 AM EDTUpdated 08:34 AM
R&D

Am­gen makes pipeline cuts, but obe­si­ty plans re­main the fo­cus

Ayisha Sharma

News Reporter

While Am­gen didn’t re­veal much about up­com­ing read­outs for its high­ly-an­tic­i­pat­ed weight loss drugs dur­ing third-quar­ter earn­ings, the com­pa­ny did de­tail cer­tain changes to oth­er …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Pfiz­er CEO says op­por­tu­ni­ties with Trump ‘clear­ly out­weigh’ the risks for phar­ma

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

Trump blog: Judge ex­tends na­tion­wide block on NIH pay­ment cuts

RFK Jr. read­ies re­view of child­hood vac­cine sched­ule af­ter pledg­ing not to

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times